What's New


May 19, 2016 - Letter: Public Citizen Joins Knowledge Ecology International, Oxfam America and Health GAP in Writing to Senator Hatch Regarding Reported Pressure On Colombia Not to License Cancer Medicine Glivic

May 18, 2016 - Washington Post: Dispute with Swiss drugmaker has Colombian officials worried about U.S. peace funding

May 18, 2016 - Press Release: Groups Warn Against Senate HELP Committee Members’ Legislative Sleight of Hand on Cures Act

May 18, 2016 - STAT: Colombia to Novartis: Lower the price of your cancer drug, or else

May 18, 2016 - Reuters: Deal still possible in Colombia-Novartis cancer drug talks : minister

For older news, visit the Access to Medicines news archive

U.S. Pressure Against Countries' Public Interest Policies


Global Access to Medicines Program Director Peter Maybarduk delivers testimony at USTR's 2014 Special 301 hearing.

Public Citizen Statement on the 2014 Special 301 Report


April 30, 2014

U.S. Chamber, Big Pharma Miss Their Target on India Trade, But U.S. Watch List Still Bullies India, Other Developing Countries Over Health Policies

Statement of Peter Maybarduk, Director, Public Citizen Global Access to Medicines Program

Note: Today, the Office of the U.S. Trade Representative (USTR) released its annual Special 301 Report. The 301 Report places countries on a watch list for practices the U.S. government believes reflect “inadequate” intellectual property (IP) protection, even when these policies safeguard important public interests including health.

The Special 301 Report's watch list is a morally repugnant and unnecessary U.S. government practice, which annually bullies countries for implementing polices that promote access to lifesaving medicines despite serious questions about the legality of such unilateral threats under international law. The 301 watch list should be discontinued in its entirety. Continue reading...

Resources

Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.